Key result
A 67-year-old male with cardiovascular comorbidities developed statin-associated muscle symptoms after resuming rosuvastatin, requiring discontinuation and transition to a PCSK9 inhibitor.
Why the study?
Statin-associated muscle symptoms complicate cardiovascular risk management by causing therapy discontinuation and pose challenges in diagnosis and treatment in patients with complex cardiovascular comorbidities.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the challenges of managing statin-associated muscle symptoms in high-risk cardiovascular patients and the utility of transitioning to PCSK9 inhibitors.
Statin-associated muscle symptoms (SAMS) are a common side effect of statin therapy, which is widely used to manage cardiovascular diseases (CVDs). These symptoms, which can range from mild muscle discomfort to more severe complications, may lead some patients to discontinue statin therapy, potentially affecting cardiovascular risk management. We present the case of a 67-year-old male patient with multiple cardiovascular comorbidities, including peripheral artery disease (PAD), who developed SAMS after resuming rosuvastatin. Management included statin discontinuation, supportive care with intravenous fluids, and transition to a non-statin lipid-lowering agent (proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor). This case highlights the diagnostic and therapeutic challenges of managing SAMS in a patient with complex cardiovascular comorbidities, particularly focusing on distinguishing myopathy from ischemic symptoms and navigating statin reintroduction versus alternative lipid-lowering strategies.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2025) conducted a case report in Statin-associated muscle symptoms (SAMS) (n=1). Rosuvastatin was evaluated. A 67-year-old male with cardiovascular comorbidities developed statin-associated muscle symptoms after resuming rosuvastatin, requiring discontinuation and transition to a PCSK9 inhibitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: